Targeted therapy for chronic respiratory disease: a new paradigm

Peter G. Gibson, Matthew J. Peters, Claire E. Wainwright

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


Targeted therapy has emerged as a highly effective treatment approach for chronic respiratory diseases. Many of these conditions have dismal outcomes; however, targeted therapy shows great results for the subgroup who respond. This represents a new way to approach these conditions and offers great promise as a future treatment direction. In severe eosinophilic asthma, therapy that targets the interleukin-5 pathway with monoclonal antibodies leads to a 50% reduction in asthma exacerbations in previously refractory disease. In cystic fibrosis, lung function improves with therapy that targets specific molecular abnormalities in the cystic fibrosis transmembrane conductance regulator to increase the probability that this chloride channel is open. In lung cancer, specifically adenocarcinoma with epidermal growth factor receptor (EGFR) mutation and overexpression of EGFR tyrosine kinase, therapy that inhibits EGFR tyrosine kinase gives better outcomes than conventional chemotherapy.

Original languageEnglish
Pages (from-to)136-140
Number of pages5
JournalThe Medical journal of Australia
Issue number3
Publication statusPublished - 20 Feb 2017
Externally publishedYes


Dive into the research topics of 'Targeted therapy for chronic respiratory disease: a new paradigm'. Together they form a unique fingerprint.

Cite this